It has taken a while but European regulators have finally followed their US counterparts and approved Piqray, making it the first targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation.

One day after reporting that its umbralisib/ublituximab combo met a PFS endpoint in CLL, TG raises $60m as it prepares for a year-end filing of the combo. Umbralisib monotherapy is under FDA review already.

Public Company Edition: The gene therapy firm’s IPO priced at $18 and ended its first day up 23.3% at $22.20 but fell to $21.50 when stocks recovered on 2 March. Also, RedHill raised $115m for product launches and Movantik purchase, and Avadel raised $65m to compete with Jazz.

A number of new products have been submitted for review at the European Medicines Agency. While marketing authorization applications from ViiV Healthcare and BioMarin Pharmaceutical are being fast-tracked, a submission from Incyte is not.